ARS Pharmaceuticals, Inc (SPRY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ARS Pharmaceuticals, Inc (SPRY) has a cash flow conversion efficiency ratio of -0.381x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-43.48 Million) by net assets ($114.26 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ARS Pharmaceuticals, Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
ARS Pharmaceuticals, Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how ARS Pharmaceuticals, Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ARS Pharmaceuticals, Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ARS Pharmaceuticals, Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
IDI Insurance Company Ltd
TA:IDIN
|
0.678x |
|
Changchun Faway Automobile Components Co Ltd
SHG:600742
|
0.066x |
|
JC Finance & Tax Interconnect Holdings Ltd
SHE:002530
|
0.030x |
|
BW Offshore Ltd
OL:BWO
|
0.266x |
|
Lumexa Imaging Holdings, Inc. Common Stock
NASDAQ:LMRI
|
0.029x |
|
Hangzhou Anysoft Information Technology Co Ltd
SHE:300571
|
0.066x |
|
Strait Innovation Internet Co Ltd
SHE:300300
|
-0.098x |
|
Hefei Department Store Group Co Ltd
SHE:000417
|
0.042x |
Annual Cash Flow Conversion Efficiency for ARS Pharmaceuticals, Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of ARS Pharmaceuticals, Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see market value of ARS Pharmaceuticals, Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $114.26 Million | $-170.87 Million | -1.495x | -2934.56% |
| 2024-12-31 | $256.80 Million | $13.55 Million | 0.053x | +120.54% |
| 2023-12-31 | $230.76 Million | $-59.27 Million | -0.257x | -74.87% |
| 2022-12-31 | $272.89 Million | $-40.08 Million | -0.147x | -126.15% |
| 2021-12-31 | $-31.27 Million | $-17.56 Million | 0.562x | +187.00% |
| 2020-12-31 | $-14.05 Million | $9.07 Million | -0.646x | -119.14% |
| 2019-12-31 | $-5.60 Million | $-18.90 Million | 3.373x | +463.71% |
| 2018-12-31 | $18.20 Million | $-16.88 Million | -0.927x | -- |
About ARS Pharmaceuticals, Inc
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is … Read more